行情

PFNX

PFNX

PFENEX
AMEX

实时行情|Nasdaq Last Sale

12.80
-0.09
-0.70%
盘后: 12.80 0 0.00% 16:00 08/13 EDT
开盘
12.75
昨收
12.89
最高
12.92
最低
12.75
成交量
71.54万
成交额
--
52周最高
14.00
52周最低
5.26
市值
4.39亿
市盈率(TTM)
-51.8009
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测PFNX价格均价为16.67,最高价位20.00,最低价为13.00。

EPS

PFNX 新闻

更多
Mid-Afternoon Market Update: Dow Rises 1%; Kforce Shares Climb On Upbeat Q2 Results
Toward the end of trading Tuesday, the Dow traded up 1.06% to 28085.22 while the NASDAQ fell 0.22% to 10,944.77. The S&P also rose, gaining 0.45% to 3,375.46.
Benzinga · 2天前
Mid-Day Market Update: Gold Plunges Over 4%; Pfenex Shares Spike Higher
Midway through trading Tuesday, the Dow traded up 0.97% to 28061.49 while the NASDAQ fell 0.19% to 10,947. The S&P also rose, gaining 0.35% to 3,372.07.
Benzinga · 2天前
Mid-Morning Market Update: Markets Mostly Higher; SYSCO Reports Q2 Loss
Following the market opening Tuesday, the Dow traded up 1.06% to 28,085.34 while the NASDAQ fell 0.57% to 10,905.91. The S&P also rose, gaining 0.26% to 3,369.12.
Benzinga · 2天前
The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10)
Benzinga · 2天前
Pfenex shares are trading higher after the company announced it will be acquired by Ligand for $12 per share in cash.
Benzinga · 2天前
A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street
Pre-open movers
Benzinga · 2天前
7 Stocks To Watch For August 11, 2020
Some of the stocks that may grab investor focus today are:
Benzinga · 2天前
PFENEX ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PFNX and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Pfenex Inc. (NYSE: PFNX) breached their fiduciary duties or violated the federal securities laws in connection wit
Business Wire · 3天前

所属板块

生物技术和医学研究
+0.99%
制药与医学研究
-0.06%

热门股票

代码
价格
涨跌幅

PFNX 简况

Pfenex Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Its next advanced product candidates are PF530 and PF708. PF530 is a biosimilar candidate to Betaseron (interferon beta-1b). PF708 is being developed as a therapeutically equivalent peptide to Forteo (teriparatide), which is for the treatment of osteoporosis. In addition to its three advanced product candidates, its pipeline includes over four other biosimilar candidates, as well as vaccines and next generation biologic candidates. Its product candidates are enabled by its protein production platform, Pfenex Expression Technology. It is also developing Px563L, an anthrax vaccine candidate, and Px533 as a prophylactic vaccine candidate against malaria infection.
展开

微牛提供Pfenex Inc(AMEX-PFNX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的PFNX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易PFNX股票基本功能。